# GCC Personalized Medicine Market > GCC Personalized Medicine Market Research Report By Product Outlook (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, Personalized Nutrition and Wellness), By Application Outlook (Oncology, CNS, Immunology, Respiratory, Others) and By End-User Outlook (Hospitals, Diagnostic Centers, Research Academic Institutes, Others) -Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.81% - **2024:** $ 15.5 Billion - **2025:** $ 16.56 Billion - **2035:** $ 32 Billion - **Key Players:** Roche (CH), Thermo Fisher Scientific (US), Illumina (US), Novartis (CH), GSK (GB), Bristol-Myers Squibb (US), Pfizer (US), Merck KGaA (DE), Amgen (US) **Report ID:** MRFR/HC/43633-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/gcc-personalized-medicine-market-45313 --- ## Market Summary ## **GCC Personalized Medicine Market Overview** As per MRFR analysis, the GCC Personalized Medicine Market Size was estimated at 8.35 (USD Billion) in 2023.The GCC Personalized Medicine Market is expected to grow from 8.95(USD Billion) in 2024 to 19.48 (USD Billion) by 2035. The GCC Personalized Medicine Market CAGR (growth rate) is expected to be around 7.326% during the forecast period (2025-2035). **Key GCC Personalized Medicine Market Trends Highlighted** The growing emphasis on customized healthcare solutions is propelling the GCC personalized medicine market's notable expansion. The increasing incidence of chronic illnesses in the area, which is pushing medical professionals to use individualized treatment plans in order to improve patient outcomes, is one of the major market drivers. Furthermore, government programs that fund biotechnology research and improve healthcare infrastructure are fostering an atmosphere that is conducive to the advancement of personalized medicine. The GCC countries have been making investments in cutting-edge medical facilities, which improve their capacity to provide individualized treatment plans. There are a lot of prospects to investigate, especially in the fields of biopharmaceutical technologies and genomics. The youthful, tech-savvy people in the area are receptive to new technologies, which facilitates the adoption of tailored medicine. Partnerships between academic institutions and medical facilities may also lead to innovations in customized therapies that are based on genetic markers unique to the GCC population. Recent trends show a rise in the use of telemedicine and digital health platforms, which enable more effective patient monitoring and distant consultations. Because healthcare practitioners can now more efficiently collect and evaluate real-time health data, this adaptation improves therapy customization. Another trend is the use of machine learning and artificial intelligence to diagnose patients and suggest treatment regimens based on their genetic makeup. A long-term shift in patient care paradigms throughout the GCC is indicated by the increased emphasis on incorporating personalized medicine into mainstream healthcare as healthcare legislation change. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **GCC Personalized Medicine Market Drivers** **Rising Prevalence of Chronic Diseases** In the GCC region, the increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer is a significant driver of the GCC Personalized Medicine Market. The World Health Organization has indicated that non-communicable diseases account for 73% of all deaths within the Gulf Cooperation Council countries, with diabetes alone affecting approximately 34% of the population in some GCC states like Qatar. This growing burden of chronic diseases necessitates the development of personalized medicine approaches that cater to individual health profiles, driving investment and innovation in this sector. Leading healthcare providers and pharmaceutical companies in the region are heavily investing in personalized treatment programs, which are further stimulated by government healthcare initiatives aimed at improving patient outcomes through tailored therapies. **Government Initiatives and Funding** Governments in the GCC region are increasingly recognizing the importance of personalized medicine, leading to various initiatives aimed at boosting its growth. In Saudi Arabia, the National Strategy for the Biotechnology Industry has established frameworks to promote advanced healthcare solutions, including personalized medicine. Additionally, the UAE's Health Ministry has launched initiatives to implement genomics in healthcare, signaling a committed effort to fund research and development in personalized therapies. Such government backing not only supports the establishment of advanced diagnostic technologies but also incentivizes partnerships between public institutions and private enterprises, thus promoting the GCC Personalized Medicine Market. **Advancements in Genomic Technologies** Significant advancements in genomic technologies are propelling the growth of the GCC Personalized Medicine Market. The decreasing costs of DNA sequencing have made genetic testing more accessible, with reports indicating a 90% reduction in sequencing costs over the last decade. In the GCC, countries like the UAE are pioneering large-scale genomic projects aimed at creating comprehensive genetic databases that facilitate personalized treatment plans. These initiatives are supported by collaborations with international organizations that specialize in genetic research, thus enhancing the scope of personalized medicine in the region. The fusion of technology and personalized treatments is likely to provide tailored healthcare solutions, addressing specific genetic predispositions among the population. **Increased Consumer Awareness and Demand** As awareness about personalized medicine grows among the public in the GCC, there is an increasing consumer demand for individualized healthcare solutions. Educational campaigns by health authorities in countries such as Kuwait and Bahrain are helping to inform the public about the benefits of personalized medicine, which is leading to a more proactive approach to healthcare among patients. This shift towards personalized healthcare is noted as consumers are increasingly seeking treatments that are tailored to their specific health needs, rather than conventional 'one-size-fits-all' solutions. Such a demand underlines the necessity for healthcare providers and stakeholders in the GCC Personalized Medicine Market to adapt and innovate, ensuring they meet the evolving expectations of patients. **GCC Personalized Medicine Market Segment Insights** **Personalized Medicine Market Product Outlook Insights** The GCC Personalized Medicine Market is evolving significantly, showcasing a robust Product Outlook with diverse applications, including Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, and Personalized Nutrition and Wellness. Personalized Medicine Diagnostics play a crucial role in the early identification of diseases, utilizing genetic testing and biomarker analysis to tailor treatment plans, driving better patient outcomes. Meanwhile, Personalized Medicine Therapeutics focuses on creating customized drug therapies that cater to individual genetic profiles, enhancing treatment efficacy and minimizing side effects, addressing the rising patient demand for tailored healthcare solutions. In addition, Personalized Medical Care emphasizes a holistic approach, integrating genetic, environmental, and lifestyle factors to devise comprehensive care strategies that improve overall health management in the GCC region. Personalized Nutrition and Wellness further complements this outlook by providing customized dietary plans based on genetic makeup and lifestyle, promoting preventive healthcare measures. Collectively, the growing awareness among healthcare professionals and patients about the benefits of personalized approaches reinforces the significance of these segments in shaping the future of the GCC healthcare landscape. The increasing investment in research and development, along with supportive government initiatives aimed at fostering innovation in healthcare, presents ample opportunities for expansion within the GCC Personalized Medicine Market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Personalized Medicine Market Application Outlook Insights** The Application Outlook for the GCC Personalized Medicine Market exhibits a diverse range of valuable applications, reflecting the growing integration of personalized approaches in healthcare. Oncology stands out as a significant area, driven by increasing cancer prevalence and advances in targeted therapies, making it a critical focus for market development. Same applies to the CNS sector, where personalized treatments for neurological disorders are gaining attention, promising improved patient outcomes. Immunology's expansion is noteworthy as well, with the rise of immunotherapies aligning with the region's healthcare initiatives to combat autoimmune diseases effectively. The respiratory segment contributes to the market by emphasizing tailored therapies for chronic conditions driven by the increasing burden of respiratory illnesses in the GCC. Additionally, the "Others" category encapsulates various emerging areas, showcasing innovative applications that cater to the region's unique healthcare needs. With the GCC countries fostering a robust healthcare infrastructure and supportive regulatory environments, the Personalized Medicine Market is set for substantial growth, backed by strong demand drivers and evolving healthcare paradigms. Market statistics indicate a shift towards more integrated and personalized healthcare solutions, making this segment increasingly vital in shaping the future of medical care in the region. **Personalized Medicine Market End-User Outlook Insights** The GCC Personalized Medicine Market exhibits a notable End-User Outlook, significantly influenced by various key segments including Hospitals, Diagnostic Centers, Research Academic Institutes, and others. Hospitals play a crucial role in the adoption of personalized medicine, often serving as primary institutions for patient management and treatment customization. Diagnostic Centers complement this by providing essential testing services that enable tailored therapies based on individual patient profiles, underscoring their importance in the overall market structure. Research Academic Institutes contribute vital insights through innovative studies and clinical trials, fostering advancements in personalized treatments. Furthermore, the 'Others' category encompasses urgent care clinics and outpatient services, which increasingly incorporate personalized approaches into patient care, elevating the overall service offerings in the region. The continuous collaboration between these segments enhances the overall efficacy of personalized medicine and demonstrates the region's commitment to modernizing healthcare through targeted treatment strategies, supported by a focus on improving patient outcomes and adapting to specific health demographics prevalent in the GCC nations. Overall, the interplay among these segments is critical, propelling the GCC Personalized Medicine Market toward significant advancements in personalized healthcare delivery. **GCC Personalized Medicine Market Key Players and Competitive Insights** The GCC Personalized Medicine Market is an evolving landscape characterized by a convergence of innovative technologies, biotechnology advancements, and a mounting focus on patient-centric approaches to healthcare. This market is particularly influenced by the rising prevalence of genetic-based diseases and the increasing demand for tailored treatment options that take into account individual patient profiles, including genetic, environmental, and lifestyle factors. With a diverse range of stakeholders, including pharmaceutical companies, healthcare providers, research institutions, and technology firms, the competitive dynamics emphasize strategic collaborations, product differentiation, and regulatory compliance to meet the unique healthcare needs of the GCC nations. The market is seeing heightened investment in research and development, as well as partnerships that aim to enhance personalized treatment methodologies and the development of robust diagnostic tools. Roche stands out prominently in the GCC Personalized Medicine Market due to its strong commitment to precision healthcare and a robust pipeline of innovative therapeutic products and diagnostic solutions. The company leverages its advanced diagnostics capabilities to provide comprehensive testing solutions that inform treatment decisions, thus enhancing patient outcomes. Roche's established presence in the GCC is bolstered by its vast network of collaborations with leading healthcare providers and research institutions within the region, enabling it to stay at the forefront of the personalized medicine paradigm. The company's focus on research and development, coupled with its existing product range tailored for specific diseases prevalent in the GCC, allows Roche to effectively cater to the unique healthcare demands and preferences of the region’s population, thereby strengthening its competitive edge. BD positions itself as a significant player in the GCC Personalized Medicine Market with its wide array of medical technologies and solutions aimed at enhancing the quality of patient care. The company specializes in a variety of key products and services, including advanced diagnostic tools, biosensors, and medication delivery systems that are integral to the implementation of personalized treatment strategies. BD's market presence is reinforced through strategic partnerships and alliances with healthcare providers and organizations in the GCC region, facilitating efficient access to innovative medical solutions. The company has also made strides in mergers and acquisitions to expand its portfolio and capabilities, allowing it to offer holistic, personalized healthcare solutions. By investing in regional initiatives and focusing on tailored strategies that meet patient and healthcare provider needs, BD continues to strengthen its position in the competitive landscape of personalized medicine within the GCC. **Key Companies in the GCC Personalized Medicine Market Include** - Roche - BD - Genzyme - AstraZeneca - Amgen - Qiagen - Novartis - Siemens Healthineers - GSK - Thermo Fisher Scientific - Curetis - Illumina - Mayo Clinic - Abbott - Veracyte **GCC Personalized Medicine****Market****Developments** The GCC Personalized Medicine Market has recently seen significant developments driven by advancements in genomics and a rising demand for tailored healthcare solutions. Notably, companies like Roche and Novartis are enhancing their product lines, focusing on targeted therapies and diagnostics that cater to the unique genetic profiles of patients in the region. In September 2023, Roche announced a strategic partnership with local healthcare organizations in Saudi Arabia aimed at boosting personalized oncology treatments. Furthermore, AstraZeneca and Amgen are investing in research to tailor therapies for chronic diseases prevalent in the GCC. The market is also witnessing mergers and acquisitions, with Qiagen acquiring a biotech firm in July 2023 to expand its molecular diagnostics capabilities in the region, enhancing its foothold amidst growing competition. The overall valuation of the GCC Personalized Medicine Market is projected to grow significantly, with the UAE and Saudi Arabia leading the charge in adopting personalized healthcare strategies. This environment is fostering innovation and collaboration between traditional pharmaceutical companies and emerging biotech firms, ultimately paving the way for more personalized healthcare solutions across the GCC. **GCC Personalized Medicine Market Segmentation Insights** **Personalized Medicine Market****Product****Outlook** **Personalized Medicine Market****Application****Outlook** **Personalized Medicine Market****End-User****Outlook** -   -   -   -   -   - Beta Beta feature ## Market Drivers ### Regulatory Framework Enhancements The personalized medicine market is benefiting from enhancements in the regulatory framework within the GCC. Regulatory bodies are increasingly recognizing the importance of personalized therapies and are streamlining approval processes for innovative treatments. This shift is likely to foster a more conducive environment for the development and commercialization of personalized medicine solutions. As of 2025, the regulatory landscape is expected to become more favorable, with initiatives aimed at expediting the review of personalized therapies. This regulatory support is crucial for the growth of the personalized medicine market, as it encourages investment and innovation in this rapidly evolving field. ### Rising Demand for Targeted Therapies The personalized medicine market is experiencing a notable increase in demand for targeted therapies, particularly in the GCC region. This shift is largely driven by the growing awareness among healthcare providers and patients regarding the benefits of tailored treatments. As of 2025, the market for targeted therapies is projected to reach approximately $50 billion, reflecting a compound annual growth rate (CAGR) of around 10%. This trend indicates a significant transformation in treatment paradigms, where therapies are designed to cater to individual genetic profiles, thereby enhancing efficacy and minimizing adverse effects. The personalized medicine market is thus positioned to capitalize on this demand, as healthcare systems increasingly prioritize precision medicine approaches to improve patient outcomes. ### Advancements in Diagnostic Technologies Technological advancements in diagnostic tools are playing a crucial role in the growth of the personalized medicine market. Innovations such as next-generation sequencing (NGS) and advanced imaging techniques are enabling more accurate and timely diagnoses. In the GCC, the market for diagnostic technologies is expected to grow by approximately 15% annually, driven by the increasing adoption of these sophisticated tools. These advancements facilitate the identification of specific biomarkers, which are essential for developing personalized treatment plans. Consequently, the personalized medicine market is likely to benefit from enhanced diagnostic capabilities, leading to improved patient stratification and treatment efficacy. ### Increased Focus on Preventive Healthcare There is a marked shift towards preventive healthcare in the GCC, which is significantly impacting the personalized medicine market. This focus on prevention is driven by rising healthcare costs and a growing awareness of the benefits of early intervention. As a result, personalized medicine approaches that emphasize risk assessment and tailored prevention strategies are gaining traction. The market for preventive healthcare solutions is anticipated to grow by approximately 12% annually, indicating a robust demand for personalized interventions. This trend suggests that the personalized medicine market will continue to evolve, aligning with the broader healthcare paradigm that prioritizes prevention over treatment. ### Growing Investment in Healthcare Infrastructure The personalized medicine market is being positively influenced by the growing investment in healthcare infrastructure across the GCC. Governments and private entities are increasingly allocating funds to enhance healthcare facilities, which is essential for the implementation of personalized medicine strategies. As of 2025, investments in healthcare infrastructure in the region are projected to exceed $100 billion, with a significant portion directed towards advanced medical technologies and research initiatives. This influx of capital is expected to bolster the personalized medicine market by providing the necessary resources for research, development, and the integration of innovative therapies into clinical practice. ## Future Outlook The [Personalized Medicine Market](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937) is projected to grow at a 6.81% CAGR from 2025 to 2035, driven by advancements in genomics, technology integration, and increasing healthcare demand. **New opportunities:** - Development of AI-driven diagnostic tools for personalized treatment plans. - Expansion of telemedicine platforms for remote patient monitoring and consultations. - Investment in biobanking for personalized drug development and research. By 2035, the personalized medicine market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Product: Personalized Medicine Diagnostics (Largest) vs. Personalized Medicine Therapeutics (Fastest-Growing) In the GCC personalized medicine market, the segment distribution reveals that Personalized Medicine Diagnostics holds the largest market share, emphasizing its critical role in patient management. Personalized Medical Care and Personalized Nutrition and Wellness also possess significant shares, reflecting the diverse approaches within personalized medicine. Personalized Medicine Therapeutics, although smaller in comparison, is witnessing rapid growth as innovations emerge in treatment methodologies. Growth trends indicate an increasing demand for tailored healthcare solutions, driven by advancements in genomics and biotechnology. The rising prevalence of chronic diseases necessitates precision medicine approaches, which are effectively provided by these personalized segments. The expansion of healthcare infrastructure in the GCC is further supporting market growth, enabling quicker adoption of innovative diagnostic and therapeutic solutions. Personalized Medicine Diagnostics (Dominant) vs. Personalized Medicine Therapeutics (Emerging) Personalized Medicine Diagnostics is characterized by its established presence and vital role in enhancing patient outcomes through tailored testing. It dominates the market due to its ability to provide accurate, individualized insights that inform treatment plans, which is crucial in the GCC healthcare landscape. In contrast, Personalized Medicine Therapeutics, while still emerging, is rapidly gaining traction as more therapies become personalized. This segment is characterized by innovation and the potential for significant advancements in treatment effectiveness, driven by biotechnology breakthroughs. As healthcare providers seek more effective solutions, the demand for tailored therapeutics is anticipated to grow, reflecting a shift towards a more personalized approach in medicine. ### By Application: Oncology (Largest) vs. CNS (Fastest-Growing) The application segment of the GCC personalized medicine market is characterized by diverse therapeutic areas including oncology, CNS, immunology, and respiratory applications. Oncology holds the largest market share due to rising cancer incidences and a growing demand for targeted therapies. In contrast, the CNS segment is gaining traction and is recognized as the fastest-growing area, driven by increasing awareness and advancements in personalized treatments for neurological disorders. Growth trends within the GCC personalized medicine market indicate a robust shift towards precision medicine, particularly in oncology and CNS applications. The increasing prevalence of chronic diseases and an aging population are key drivers fuelling the demand for personalized therapeutics. Furthermore, substantial investments in research and development are propelling innovations, making personalized treatments more effective and accessible, thus enhancing market growth prospects. Oncology (Dominant) vs. CNS (Emerging) Oncology remains the dominant segment in the GCC personalized medicine market, attributed to the critical need for tailored treatments in combating various forms of cancer. Innovations such as immunotherapy and targeted drug delivery have significantly improved outcomes for cancer patients. On the other hand, the CNS segment, while emerging, is quickly evolving with breakthroughs in understanding neurological conditions. The growth of personalized treatments for disorders like Alzheimer's and Parkinson's is indicative of a shifting focus. Both segments showcase unique characteristics: oncology represents established therapies with substantial market presence, while CNS signifies the potential for rapid advancements and increasing investment, positioning it as a significant area for future growth. ### By End-User: Hospitals (Largest) vs. Diagnostic Centers (Fastest-Growing) In the GCC personalized medicine market, the market share distribution reveals that hospitals constitute the largest segment, showcasing their critical role in patient care and treatment delivery. Diagnostic centers follow, capturing a significant portion while also exhibiting considerable growth potential in the landscape of personalized therapies. Research and academic institutes, while valuable, hold a smaller share, primarily focusing on innovation and development rather than immediate market applications. The growth trends in this segment are indicative of a shift towards more personalized healthcare solutions and an increased emphasis on targeted treatments. Factors driving this growth include a burgeoning awareness of personalized medicine's benefits among healthcare providers, advancements in genomic and diagnostic technologies, and an uptick in investments from both public and private sectors aimed at enhancing healthcare facilities and services, particularly in hospitals and diagnostic centers. Hospitals: Dominant vs. Diagnostic Centers: Emerging Hospitals play a dominant role in the GCC personalized medicine market, serving as the primary point for personalized healthcare delivery. Their extensive infrastructure, experienced staff, and comprehensive treatment capabilities allow them to integrate personalized medical practices effectively, thereby improving patient outcomes. In contrast, diagnostic centers are emerging rapidly, showcasing advancements in testing technologies and methodologies that cater to personalized approaches. These facilities are crucial for early detection and diagnosis, enabling more precise treatment plans. While hospitals focus on treatment delivery, diagnostic centers emphasize testing and analysis, making both segments integral to the expanding ecosystem of personalized healthcare. Their collaborative synergy fosters comprehensive care tailored to individual patient needs, supporting the overarching goal of personalized medicine. ## Competitive Benchmarking The personalized medicine market is currently characterized by a dynamic competitive landscape, driven by rapid advancements in genomics, biotechnology, and data analytics. Key players are increasingly focusing on innovation and strategic partnerships to enhance their market positioning. Companies such as Roche (CH), Thermo Fisher Scientific (US), and Novartis (CH) are at the forefront, leveraging their extensive research capabilities and technological expertise to develop tailored therapies. Roche (CH) emphasizes its commitment to precision medicine through continuous investment in R&D. Meanwhile, Thermo Fisher Scientific (US) is enhancing its portfolio with cutting-edge diagnostic tools that facilitate personalized treatment pathways. Novartis (CH) is actively pursuing collaborations with biotech firms to expand its personalized medicine offerings, thereby shaping a competitive environment that prioritizes innovation and strategic alliances. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the personalized medicine market appears moderately fragmented, with several key players exerting substantial influence. This fragmentation allows for a diverse range of products and services, fostering innovation while also presenting challenges in terms of market share and customer loyalty. In October Roche (CH) announced a strategic partnership with a leading AI firm to develop predictive analytics tools aimed at improving patient outcomes in personalized therapies. This collaboration is expected to enhance Roche's capabilities in data-driven decision-making, potentially leading to more effective treatment protocols and a stronger market position. The integration of AI into their operations signifies a pivotal shift towards technology-driven healthcare solutions. In September Thermo Fisher Scientific (US) launched a new suite of genomic sequencing products designed specifically for personalized medicine applications. This launch not only expands their product line but also positions them as a leader in the rapidly evolving field of genomics. The strategic importance of this move lies in its potential to attract a broader customer base, including research institutions and healthcare providers, thereby solidifying Thermo Fisher's competitive edge. In August Novartis (CH) entered into a collaboration with a prominent digital health company to enhance its personalized medicine initiatives. This partnership aims to integrate digital health solutions into Novartis's therapeutic offerings, thereby improving patient engagement and adherence to treatment regimens. The strategic significance of this collaboration is underscored by the growing importance of digital tools in managing chronic diseases and optimizing treatment outcomes. As of November current trends in the personalized medicine market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are playing a crucial role in shaping the competitive landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, it appears that competitive differentiation will increasingly hinge on technological advancements and supply chain reliability, rather than solely on price. This shift suggests a future where innovation and the ability to deliver personalized solutions will be paramount in maintaining a competitive advantage. ## Recent News & Developments The GCC Personalized Medicine Market has recently seen significant developments driven by advancements in genomics and a rising demand for tailored healthcare solutions. Notably, companies like Roche and Novartis are enhancing their product lines, focusing on targeted therapies and diagnostics that cater to the unique genetic profiles of patients in the region. In September 2023, Roche announced a strategic partnership with local healthcare organizations in Saudi Arabia aimed at boosting personalized oncology treatments. Furthermore, AstraZeneca and Amgen are investing in research to tailor therapies for chronic diseases prevalent in the GCC. The market is also witnessing mergers and acquisitions, with Qiagen acquiring a biotech firm in July 2023 to expand its molecular diagnostics capabilities in the region, enhancing its foothold amidst growing competition. The overall valuation of the GCC Personalized Medicine Market is projected to grow significantly, with the UAE and Saudi Arabia leading the charge in adopting personalized healthcare strategies. This environment is fostering innovation and collaboration between traditional pharmaceutical companies and emerging biotech firms, ultimately paving the way for more personalized healthcare solutions across the GCC. ## Report Scope | MARKET SIZE 2024 | 15.5(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 16.56(USD Billion) | | MARKET SIZE 2035 | 32.0(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.81% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Roche (CH), Thermo Fisher Scientific (US), Illumina (US), Novartis (CH), GSK (GB), Bristol-Myers Squibb (US), Pfizer (US), Merck KGaA (DE), Amgen (US) | | Segments Covered | Product, Application, End-User | | Key Market Opportunities | Integration of artificial intelligence in personalized medicine enhances treatment precision and patient outcomes. | | Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the personalized medicine market. | | Countries Covered | GCC | ## Frequently Asked Questions **Q: What was the overall valuation of the personalized medicine market in 2024?** A: The overall market valuation was $15.5 Billion in 2024. **Q: What is the projected market valuation for personalized medicine by 2035?** A: The projected valuation for 2035 is $32.0 Billion. **Q: What is the expected CAGR for the GCC personalized medicine market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 6.81%. **Q: Which segments are included in the personalized medicine market?** A: The market includes segments such as Personalized Medicine Diagnostics, Therapeutics, Medical Care, and Nutrition and Wellness. **Q: What was the valuation of Personalized Medicine Diagnostics in 2024?** A: In 2024, the valuation of Personalized Medicine Diagnostics was $3.1 Billion. **Q: How much is the Personalized Medicine Therapeutics segment projected to grow by 2035?** A: The Personalized Medicine Therapeutics segment is projected to grow to $10.5 Billion by 2035. **Q: Which applications are driving growth in the personalized medicine market?** A: Key applications include Oncology, CNS, Immunology, and Respiratory, with Oncology valued at $5.0 Billion in 2024. **Q: What is the expected valuation for the Hospitals end-user segment by 2035?** A: The Hospitals end-user segment is expected to reach $12.8 Billion by 2035. **Q: Who are the key players in the personalized medicine market?** A: Key players include Roche, Thermo Fisher Scientific, Illumina, Novartis, GSK, Bristol-Myers Squibb, Pfizer, Merck KGaA, and Amgen. **Q: What was the valuation of the Personalized Medical Care segment in 2024?** A: The valuation of the Personalized Medical Care segment was $4.0 Billion in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gcc-personalized-medicine-market-45313*